Hoth Therapeutics, Inc.

NasdaqCM HOTH

Hoth Therapeutics, Inc. Return on Assets (ROA) for the Trailing 12 Months (TTM) ending September 30, 2024

Hoth Therapeutics, Inc. Return on Assets (ROA) is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
Loading...
SV Wall Street
NasdaqCM: HOTH

Hoth Therapeutics, Inc.

CEO Mr. Robb Knie
IPO Date Feb. 15, 2019
Location United States
Headquarters 1 Rockefeller Plaza
Employees 2
Sector Health Care
Industries
Description

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.

Similar companies

VRAX

Virax Biolabs Group Limited

USD 1.69

0.00%

PHIO

Phio Pharmaceuticals Corp.

USD 2.03

2.01%

ZURA

Zura Bio Limited

USD 1.77

-0.56%

ALLR

Allarity Therapeutics, Inc.

USD 1.04

-3.70%

SONN

Sonnet BioTherapeutics Holdings, Inc.

USD 1.62

-1.22%

BDRX

Biodexa Pharmaceuticals Plc

USD 4.41

4.01%

REVB

Revelation Biosciences, Inc.

NA

NA

KPRX

Kiora Pharmaceuticals, Inc.

USD 3.69

-2.64%

ATNF

180 Life Sciences Corp.

USD 1.38

-0.72%

ATXI

Avenue Therapeutics, Inc.

USD 1.30

-2.99%

StockViz Staff

February 7, 2025

Any question? Send us an email